Cargando…

Intravenous Steroids for Refractory Chemotherapy-Related Diarrhea: A Case Report

The clinical course of a patient with chemotherapy-related diarrhea (CRD) refractory to standard therapy was monitored over the course of 21 days. The patient was minimally responsive to traditional treatment options, including bismuth subsalicylate, diphenoxylate-atropine, loperamide, octreotide, a...

Descripción completa

Detalles Bibliográficos
Autores principales: Patel, Kishan, Dang, Adrian, Makhlouf, Mai M, Raman, Alex G, Abdulla, Nihal E
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9989110/
https://www.ncbi.nlm.nih.gov/pubmed/36895532
http://dx.doi.org/10.7759/cureus.34634
_version_ 1784901700776099840
author Patel, Kishan
Dang, Adrian
Makhlouf, Mai M
Raman, Alex G
Abdulla, Nihal E
author_facet Patel, Kishan
Dang, Adrian
Makhlouf, Mai M
Raman, Alex G
Abdulla, Nihal E
author_sort Patel, Kishan
collection PubMed
description The clinical course of a patient with chemotherapy-related diarrhea (CRD) refractory to standard therapy was monitored over the course of 21 days. The patient was minimally responsive to traditional treatment options, including bismuth subsalicylate, diphenoxylate-atropine, loperamide, octreotide, and oral (PO) steroids, and exhibited reportable improvements with the addition of intravenous (IV) methylprednisolone to other antidiarrheal agents. We present a case of CRD in an 82-year-old female. She was initiated on chemotherapy three weeks prior and has experienced severe diarrhea since her initiation. Despite the use of first-line antidiarrheal therapies, including loperamide, diphenoxylate-atropine, and octreotide, both subcutaneously and via continuous infusion drip, no infectious cause was found. She also received the non-absorbing corticosteroid budesonide, but her diarrhea persisted. After experiencing severe hypotension and hypovolemia secondary to profuse diarrhea, she was placed on IV steroids, which quickly reduced her symptoms. The patient was then transitioned to oral steroids and discharged on a tapering regimen. We recommend using IV steroids to treat CRD if first-line therapies fail. Utilizing IV steroids efficiently and effectively can decrease the symptoms of persistent diarrhea and lead to rapid recovery.
format Online
Article
Text
id pubmed-9989110
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Cureus
record_format MEDLINE/PubMed
spelling pubmed-99891102023-03-08 Intravenous Steroids for Refractory Chemotherapy-Related Diarrhea: A Case Report Patel, Kishan Dang, Adrian Makhlouf, Mai M Raman, Alex G Abdulla, Nihal E Cureus Internal Medicine The clinical course of a patient with chemotherapy-related diarrhea (CRD) refractory to standard therapy was monitored over the course of 21 days. The patient was minimally responsive to traditional treatment options, including bismuth subsalicylate, diphenoxylate-atropine, loperamide, octreotide, and oral (PO) steroids, and exhibited reportable improvements with the addition of intravenous (IV) methylprednisolone to other antidiarrheal agents. We present a case of CRD in an 82-year-old female. She was initiated on chemotherapy three weeks prior and has experienced severe diarrhea since her initiation. Despite the use of first-line antidiarrheal therapies, including loperamide, diphenoxylate-atropine, and octreotide, both subcutaneously and via continuous infusion drip, no infectious cause was found. She also received the non-absorbing corticosteroid budesonide, but her diarrhea persisted. After experiencing severe hypotension and hypovolemia secondary to profuse diarrhea, she was placed on IV steroids, which quickly reduced her symptoms. The patient was then transitioned to oral steroids and discharged on a tapering regimen. We recommend using IV steroids to treat CRD if first-line therapies fail. Utilizing IV steroids efficiently and effectively can decrease the symptoms of persistent diarrhea and lead to rapid recovery. Cureus 2023-02-04 /pmc/articles/PMC9989110/ /pubmed/36895532 http://dx.doi.org/10.7759/cureus.34634 Text en Copyright © 2023, Patel et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Internal Medicine
Patel, Kishan
Dang, Adrian
Makhlouf, Mai M
Raman, Alex G
Abdulla, Nihal E
Intravenous Steroids for Refractory Chemotherapy-Related Diarrhea: A Case Report
title Intravenous Steroids for Refractory Chemotherapy-Related Diarrhea: A Case Report
title_full Intravenous Steroids for Refractory Chemotherapy-Related Diarrhea: A Case Report
title_fullStr Intravenous Steroids for Refractory Chemotherapy-Related Diarrhea: A Case Report
title_full_unstemmed Intravenous Steroids for Refractory Chemotherapy-Related Diarrhea: A Case Report
title_short Intravenous Steroids for Refractory Chemotherapy-Related Diarrhea: A Case Report
title_sort intravenous steroids for refractory chemotherapy-related diarrhea: a case report
topic Internal Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9989110/
https://www.ncbi.nlm.nih.gov/pubmed/36895532
http://dx.doi.org/10.7759/cureus.34634
work_keys_str_mv AT patelkishan intravenoussteroidsforrefractorychemotherapyrelateddiarrheaacasereport
AT dangadrian intravenoussteroidsforrefractorychemotherapyrelateddiarrheaacasereport
AT makhloufmaim intravenoussteroidsforrefractorychemotherapyrelateddiarrheaacasereport
AT ramanalexg intravenoussteroidsforrefractorychemotherapyrelateddiarrheaacasereport
AT abdullanihale intravenoussteroidsforrefractorychemotherapyrelateddiarrheaacasereport